The investigational PRAME-targeted T-cell therapy IMA203 generated responses in melanoma and other solid tumors,
Of Interest
RP1 Plus Nivolumab Is Active, Safe in Advanced Melanoma After Progression on Anti–PD-1 Therapy
RP1 plus nivolumab generated responses in advanced melanoma that progressed on or after prior anti–PD-1 therapy.
Novel Combo Shows Early Activity in PD-L1–Resistant NSCLC, Melanoma
Glycan editing of cell surface glycans with E-602 may represent a novel therapeutic approach among patients with cancer.
From melanoma to malaria: photoacoustic device detects disease without taking a single drop of blood
Malaria remains a serious health concern, with annual deaths increasing yearly since 2019 and almost half of the world’s population at risk of infection.